Deutsche Bank analyst David Hoang raised the firm’s price target on Sarepta (SRPT) to $12 from $6 and keeps a Sell rating on the shares. After analyzing Elevidys demand post-patient deaths, the firm says the gene therapy’s “woes may not be over yet.”
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta loses credibility by exiting Arrowhead at loss, says H.C. Wainwright
- Sarepta Therapeutics Announces Strategic Restructuring Plan
- Arrowhead redeems $50M of common stock
- Video: Nvidia, AMD said to pay U.S. 15% of revenue from China chip sales
- SRPT Lawsuit Alert! Class Action Lawsuit Against Sarepta Therapeutics